3C
PETX

361 Capital’s Aratana Therapeutics, Inc. PETX Stock Holding History

361 Capital’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-55,948
Closed -$405K – 314
2017
Q2 		$405K Buy
+55,948
New +$344K 0.07% 147

Other funds holding PETX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

361 Capital's PETX Position: Q3 2017 in Review

361 Capital sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2017, closing a stake of 55,948 shares — an estimated $405K sold.

361 Capital first reported a position in PETX in Q2 2017 and held it in 1 quarter. The position peaked at $405K in Q2 2017. 96 funds tracked by Wall St. Rank hold PETX as of Q3 2017.

  • 361 Capital reported no remaining Aratana Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
  • 361 Capital sold 55,948 Aratana Therapeutics, Inc. shares in Q3 2017, an estimated $405K.
  • 361 Capital first reported a position in Aratana Therapeutics, Inc. in Q2 2017 and held it in 1 quarter.
  • 361 Capital's Aratana Therapeutics, Inc. position peaked at $405K in Q2 2017.
  • 96 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2017.

Based on 361 Capital's 13F filing for Q3 2017, filed 7 Nov 2017.